Free delivery over $100 Learn more

30 days return period Learn more
SKU: 0041ATC

HT-55 Human Rectum Adenocarcinoma Epithelial Cells

Tumor Cell Lines > Colon Cancer Cell Lines

Product Type: Human Colon Cancer Cell Lines

Species: Human

Cell Type: Epithelial Cells

Source Organ: Intestine

$1,249.00
Size

Care information

Display general product information or specific product information using metafields.

Delivery and Shipping

Add some general information about your delivery and shipping policies.

Cell Name: HT-55

Human colon carcinoma. Human colon epithelial cell line.

  • Description
    The HT-55 is a human colon cancer cell line derived from the rectum of a 54-year-old white female patient with rectal adenocarcinoma. The cells display well-differentiated cancer morphology and grow in adherent clumps that resemble columnar epithelium with a clear border. These clumps show an island growth pattern, forming multiple layers at the center. HT-55 cells retain certain intestinal epithelial functional characteristics, including the expression of epithelial cell polarity-related proteins, but their specific secretory functions have not yet been fully elucidated. As a rectal adenocarcinoma model, this cell carries multiple colorectal cancer characteristic gene mutations: APC gene (p.Gln1131Ter, p.Gln1303Ter, p.Arg1463Ser), TP53 gene (p.Arg213Leu), BRAF gene (p.Asn581Tyr) and DNMT3A gene (p.Lys241Ter), etc. These mutation spectra make it an ideal model for studying the pathogenesis and targeted therapy of colorectal cancer.
  • Product Name
    HT-55
  • Product Type
    Human Colon Cancer Cell Lines
  • Species
    Human
  • Cell Type
    Epithelial
  • Source Organ
    Rectum
  • Disease
    Rectal Adenocarcinoma
  • Product Type
    Human Colon Cancer Cell Lines
  • Growth Conditions
    37 °C, 5% CO2
  • Application
    HT-55 is a valuable model for studying potential therapies for human rectal cancer. In studies involving HT-55, cell proliferation and death can be affected by anti-cancer drugs through the ERK 1/2, p38-MAPK, and PI3K/AKT pathways of ERK 1/2, p38-MARK, and PI3K/AKT. Further investigation can explore the utilization of existing anti-cancer therapy targeting these pathways in HT-55. Moreover, a BRAF mutation (N581Y) has been detected in HT-55, indicating that HT-55 can help improve strategies combining anti-EGFR monoclonal antibodies with BRAF inhibitors for BRAF mutant cancers to elucidate the molecular pathogenesis of colorectal cancer.
  • Size/Quantity
    1 vial
  • Recommended Medium And Supplement

    EMEM + 2mM Glutamine + 1% Non Essential Amino Acids + 20% FBS
  • Shipping Conditions
    Dry Ice
  • Storage
    Liquid Nitrogen
  • Biosafety Level
    1

Payment & Security

Payment methods

    Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

    • Visit our support center

      Expert help & advice

    • Check your order status

      Updates & tracking

    • Returns & exchanges

      All you need to know

    • Price-match guarantee

      Our promise to you